Table 2.
Multivariable association between novel oral anticoagulant use and gastrointestinal bleeding
| Analysis | Dabigatran (reference group: warfarin) | Rivaroxaban (reference group: warfarin) |
|---|---|---|
| All patients: | (n=44 514) | (n=41 256) |
| Crude hazard ratio* (95% CI) | 1.20 (0.96 to 1.52) | 0.95 (0.31 to 2.94) |
| Adjusted hazard ratio† (95% CI) | 1.21 (0.96 to 1.53) | 0.98 (0.36 to 2.69) |
| Patients aged under 65 years: | (n=34 038) | (n=32 099) |
| Crude hazard ratio* (95% CI) | 1.33 (0.98 to 1.80) | 1.08 (0.27 to 4.41) |
| Adjusted hazard ratio† (95% CI) | 1.34 (0.98 to 1.83) | 1.03 (0.33 to 3.18) |
| Patients aged over 65 years: | (n=10 476) | (n=9157) |
| Crude hazard ratio* (95% CI) | 1.07 (0.75 to 1.52) | 0.69 (0.10 to 4.68) |
| Adjusted hazard ratio† (95% CI) | 1.07 (0.75 to 1.53) | 0.62 (0.18 to 2.08) |
Source: IMS Health LifeLink® Health Plan Claims Database, 2010-12.
*No control variables.
†Age groups, Clinical Classification Software categories, and non-steroidal anti-inflammatory drug use as stratification factors and others as regression covariates.